Amendment Flag
Current Fiscal Year End Date
Document Period End Date
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Filer Category
Entity Public Float
Entity Registrant Name
Entity Central Index Key
Entity Common Stock, Shares Outstanding
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Type
Award Type [Axis]
Collaborative Arrangements Transactions [Domain]
Summary of significant accounting policies [Abstract]
Accounts receivable
Accounts Receivable, Net, Current
Net receivable from collaboration agreements
Accounts payable
Accounts Payable, Current
Accrued expenses and other current liabilities
Accumulated other comprehensive loss
Additional paid-in capital
Adjustments to reconcile to net cash provided by (used in) operating activities:
All Other [Member]
Amortization for intangible assets
Amortization of Intangible Assets
Antidilutive Securities [Axis]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities, Name [Domain]
Antidilutive shares excluded from calculation (in shares)
Assets:
Total assets
Total assets
Assets
Current assets:
ASSETS
Assets [Abstract]
Intangible assets, net
Total current assets
Assets, Current
Total assets
Assets, Fair Value Disclosure
Investments
Available-for-sale Securities, Debt Securities, Current
Business Acquisition [Axis]
Business Acquisition [Line Items]
Business Acquisition, Acquiree [Domain]
Acquisition of Healthcare Protective Products Division [Abstract]
Acquisition of Healthcare Protective Products Division [Text Block]
Contingent purchase consideration obligations
Acquisition transaction costs
Business Combination, Acquisition Related Costs
Purchases of property, plant and equipment unpaid at year end
Restricted cash
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Net increase (decrease) in cash and cash equivalents
Cash and Cash Equivalents, Period Increase (Decrease)
Cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Cash and cash equivalents
Cash and Cash Equivalents, Policy [Policy Text Block]
Investment in money market funds (1)
Cash and Cash Equivalents, Fair Value Disclosure
Chief Executive Officer [Member]
Variable Interest Entity, Classification [Domain]
Collaborative arrangements [Line Items]
Collaboration Agreements
Collaborative Arrangement Disclosure [Text Block]
Commitments and contingencies
Common stock, par value (in dollars per share)
Common stock, $0.001 par value; 100,000,000 shares authorized, 36,714,299 shares issued and 36,311,141 shares outstanding at September 30, 2013; 36,272,550 shares issued and 35,869,392 shares outstanding at December 31, 2012
Common stock, shares issued (in shares)
Common stock, voting rights
Common stock, shares authorized (in shares)
Common stock, shares outstanding (in shares)
Common stock
Comprehensive income
Comprehensive income
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Concentrations of credit risk
Consolidation Items [Domain]
Basis of presentation and consolidation
Consolidation Items [Axis]
Contingent Consideration Type [Domain]
Contingent Consideration by Type [Axis]
Contract termination costs [Member]
Contracts and grants revenue
Contracts and grants
Cost of product sales
Cost of Sales [Member]
Tax benefit from stock options exercised
Current and deferred income taxes
Deferred revenue
Deferred revenue, net of current portion
Deferred tax assets, net
Deferred Tax Assets, Net of Valuation Allowance, Current
Deferred tax assets, net
Depreciation and amortization
Earnings per share
Earnings Per Share [Text Block]
Earnings Per Share
Income per share - basic
Income per share-basic
Income per share - diluted
Income per share-diluted
Earnings per share [Abstract]
Effect of exchange rate changes on cash and cash equivalents
Accrued compensation
Employee-related Liabilities, Current
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock Options [Member]
Total stock-based compensation expense
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount
Equity Component [Domain]
Excess tax benefits from stock-based compensation
Excess Tax Benefit from Share-based Compensation, Operating Activities
Excess tax benefits from stock-based compensation
Fair Value by Measurement Frequency [Axis]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]
Fair Value, Hierarchy [Axis]
Settlements
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Fair Value, Measurements, Recurring [Member]
Fair Value, Measurement Frequency [Domain]
Fair value of measurements
Transfers in/(out) of Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance beginning of period
Balance End of period
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value
Fair value measurements [Abstract]
Fair Value, Measurements, Fair Value Hierarchy [Domain]
Fair value measurements
Fair Value Disclosures [Text Block]
Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)
Fair Value, Inputs, Level 3 [Member]
Unobservable Input Reconciliation [Roll Forward]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Expense (income) included in earnings
Expense (income) included in comprehensive income (loss)
Purchases, sales, issuances and settlements
Finite-Lived Intangible Assets, Major Class Name [Domain]
Finite-Lived Intangible Assets by Major Class [Axis]
Foreign currencies
General and Administrative [Member]
General and Administrative Expense [Member]
Goodwill
Goodwill
In-process research and development and goodwill
Goodwill [Line Items]
In-process research and development and goodwill [Abstract]
Goodwill
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]
Intersegment Eliminations [Member]
Impairment of long-lived assets
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
Impairment of in-process research and development
Impairment of IPR&D assets
Impairment of long-lived assets
Acquired in process research and development
Consolidated Statements of Operations (unaudited) [Abstract]
Income before provision for income taxes
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest
Income Statement Location [Axis]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]
Income Statement Location [Domain]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]
Provision for income taxes
Cash paid during the year for income taxes
Income tax receivable, net
Income taxes
Accounts receivable
Increase (Decrease) in Accounts Receivable
Accounts payable
Accrued expenses and other liabilities
Deferred revenue
Increase (Decrease) in Deferred Revenue
Changes in operating assets and liabilities:
Inventories
Increase (Decrease) in Inventories
Accrued compensation
Income taxes
Increase (Decrease) in Income Taxes Receivable
Prepaid expenses and other assets
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Dilutive securities-equity awards (in shares)
Interest expense
Interest Expense
Capitalized interest
Interest Capitalization, Policy [Policy Text Block]
Cash paid during the year for interest
Inventories
Total inventories
Inventory, Net
Finished goods
Inventories
Inventory Disclosure [Text Block]
Raw materials and supplies
Inventories
Inventories [Abstract]
Work-in-process
Interest income
Interest revenue
Investment
Total current liabilities
Liabilities, Current
Total liabilities and stockholders' equity
Liabilities and Equity
Current liabilities:
Total liabilities
Liabilities
LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities:
Total liabilities
Financial and Nonfinancial Liabilities, Fair Value Disclosure
Total long-term indebtedness
Fair value of long-term indebtedness
Long-term indebtedness [Abstract]
Long-term indebtedness, current portion
Long-term indebtedness, net of current portion
Long-term Debt, Excluding Current Maturities
Significant customers and accounts receivable
Maximum [Member]
Minimum [Member]
Variable interest entities
Noncontrolling Interest Disclosure [Text Block]
Noncontrolling interest in subsidiaries
Nature of Error [Domain]
Cash flows from financing activities:
Numerator:
Net Income (Loss) Available to Common Stockholders, Basic [Abstract]
Cash flows from investing activities:
Net cash used in investing activities
Net Cash Provided by (Used in) Investing Activities
Cash flows from operating activities:
Net cash provided by financing activities
Net Cash Provided by (Used in) Financing Activities
Net cash provided by operating activities
Net Cash Provided by (Used in) Operating Activities
Net income attributable to Emergent BioSolutions Inc.
Net income attributable to Emergent BioSolutions Inc.
Net income
Net Income (Loss) Attributable to Parent
Net loss attributable to noncontrolling interest
Net Income (Loss) Attributable to Noncontrolling Interest
Recent accounting pronouncements
Total other income (expense)
Nonoperating Income (Expense)
Other income (expense):
Number of business segments
Noncontrolling Interests [Member]
Variable interest entities [Abstract]
Operating expenses:
Income from operations
Operating Income (Loss)
Other costs [Member]
Foreign currency translations, net of tax
Other assets
Other
Other Noncash Income (Expense)
Non-cash development expenses from joint venture
Supplemental information on non-cash investing and financing activities:
Other income (expense), net
Other liabilities
Emergent BioSolutions Inc. [Member]
Purchase of treasury stock
Payments for Repurchase of Common Stock
Acquisition of Healthcare Protective Products Division
Payments to Acquire Businesses, Net of Cash Acquired
Amount paid
Payments for Restructuring
Purchases of property, plant and equipment
Payments to Acquire Property, Plant, and Equipment
Purchase of investments
Payments to Acquire Available-for-sale Securities, Debt
Plan Name [Domain]
Plan Name [Axis]
Preferred stock, par value (in dollars per share)
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively
Preferred stock
Preferred stock, shares issued (in shares)
Preferred stock, shares authorized (in shares)
Preferred stock, shares outstanding (in shares)
Prepaid expenses and other current assets
Reclassification
Proceeds from collaborators
Proceeds from sale of assets
Restricted cash
Proceeds from (Repayments of) Restricted Cash, Financing Activities
Repayment of note receivable
Issuance of common stock subject to employee equity plans
Proceeds from maturity of investments
Net income
Net income
Net loss
Net income (loss)
Property, plant and equipment
Property, plant and equipment, net
Quantifying Misstatement in Current Year Financial Statements, Amount
Nature of Error [Axis]
Range [Axis]
Range [Domain]
Recognition of deferred revenue
Related Party Transaction [Line Items]
Related Party [Axis]
Related Party [Domain]
Principal payments on long-term indebtedness
Repayments of Long-term Debt
Research and development
Research and Development [Member]
Research and Development Expense [Member]
Research and development
Research and Development Expense, Policy [Policy Text Block]
Restricted Stock Units (RSUs) [Member]
Restricted cash
Restricted Cash and Cash Equivalents, Current
Inception to date costs incurred
Total expected to be incurred
Expenses incurred
Restructuring expenses
Restructuring Plan [Domain]
Restructuring Type [Axis]
Balance at December 31, 2012
Balance at September 30, 2013
Restructuring Reserve
Restructuring [Abstract]
Restructuring Plan [Axis]
Incurred as of September 30, 2013
Restructuring and Related Cost, Incurred Cost
Summary of activity for liabilities [Roll Forward]
Restructuring
Restructuring and Related Activities Disclosure [Text Block]
Restructuring Cost and Reserve [Line Items]
Other adjustments
Retained earnings
Revenues related to collaborative research funding
Revenue recognition
Revenue related to achievement of a development milestone
External revenue
Exercisable, beginning of period
Exercisable, end of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Weighted average remaining contractual term of options exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Weighted average remaining contractual term of options outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Product sales
Total revenues
Revenue, Net
Revenues:
Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Option award activity
Assumptions used in valuing stock options granted
Inventories
Schedule of Inventory, Current [Table Text Block]
Restricted stock units activity
Summary of basic and diluted net income per share
Schedule of Business Acquisitions, by Acquisition [Table]
Schedule of Collaborative Arrangements Transactions [Table]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
Schedule of Goodwill [Table]
Schedule of Related Party Transactions, by Related Party [Table]
Schedule of Restructuring and Related Costs [Table]
Costs of the restructuring
Summary of the activity for liabilities related to EPDU restructuring
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Segment Reporting Information, by Segment [Table]
Schedule of Variable Interest Entities [Table Text Block]
Schedule of Variable Interest Entities [Table]
Segment Reporting Information [Line Items]
Segments [Domain]
Segment [Domain]
Segment information [Abstract]
Segment information
Segment Reporting Disclosure [Text Block]
Selling, General and Administrative Expenses [Member]
Selling, general and administrative
Selling, General and Administrative Expense
Aggregate intrinsic value [Abstract]
Restricted stock unit award activity [Roll Forward]
Weighted-Average Exercise Price [Roll Forward]
Granted (in shares)
Granted (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Granted (in dollars per share)
Share Repurchase Program [Axis]
Outstanding, beginning of period (in shares)
Outstanding, end of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Vested (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Stock-based compensation expense
Maximum number of shares that may be granted per year to a single participant (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee
Weighted-Average Grant Price [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning of period (in dollars per share)
Outstanding, end of period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share Repurchase Program [Domain]
Forfeited (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Forfeited (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Discount from Market Price, Offering Date
Exercised (in dollars per share)
Granted (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Exercisable, beginning of period (in dollars per share)
Exercisable, end of period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Vested (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Exercisable, beginning of period (in shares)
Exercisable, end of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Employee Subscription Rate
Aggregate Intrinsic Value [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Common stock available for future awards (in shares)
Total intrinsic value of options exercised
Common stock authorized for issuance under the plan (in shares)
Weighted average grant date fair value of options granted (in dollars per share)
Forfeited (in dollars per share)
Forfeited (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Outstanding, beginning of period (in dollars per share)
Outstanding, end of period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Accounting for stock-based compensation
Outstanding, beginning of period (in shares)
Outstanding, end of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Options expected to vest, end of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Outstanding, beginning of period
Outstanding, end of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Options outstanding [Roll Forward]
Award Type [Domain]
Options expected to vest, end of period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Options expected to vest, end of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Summary of significant accounting policies
Significant Accounting Policies [Text Block]
Termination benefits [Member]
Statement [Table]
Statement [Line Items]
Consolidated Statements of Cash Flows (unaudited) [Abstract]
Statement, Equity Components [Axis]
Consolidated Statements of Comprehensive Income (unaudited) [Abstract]
Consolidated Balance Sheets (unaudited) [Abstract]
Segments [Axis]
Business Segments [Axis]
Statement, Business Segments [Axis]
Stock repurchased as part of stock swap, value
Stock repurchased as part of stock swap (in shares)
Stock Repurchase Program, Authorized Amount
Stock repurchased during period, value
Issuance of common stock to acquire Trubion Pharmaceuticals, Inc.
Stock Options [Member]
Stock Compensation Plan [Member]
Exercised (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Stock repurchased during period (in shares)
Stockholders' equity:
Other
Stockholders' Equity, Other
Total Emergent BioSolutions Inc. stockholders' equity
Stockholders' Equity Attributable to Parent
Total stockholders' equity
Stockholders' equity at December 31, 2012
Stockholders' equity at September 30, 2013
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Stockholders' equity [Abstract]
Stockholders' equity
Supplemental disclosure of cash flow information:
Taxes Payable, Current, Total
Taxes Payable, Current
Treasury Stock ( in Shares)
Treasury stock, at cost, 403,158 common shares at September 30, 2013 and December 31, 2012
Treasury Stock, Value
Collaborative Arrangements [Axis]
Type of Restructuring [Domain]
Use of estimates
Assets
Variable Interest Entity, Consolidated, Carrying Amount, Assets
Variable Interest Entities by Classification of Entity [Axis]
Non-cash development expenses from variable interest entities
Variable Interest Entity, Measure of Activity, Expense
Liabilities
Variable Interest Entity, Consolidated, Carrying Amount, Liabilities
Variable Interest Entity [Line Items]
Ownership percentage of variable interest entity (in hundredths)
Net losses included in the Company's consolidated statement of operations
Denominator:
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted-average number of shares - basic
Weighted-average number of shares-basic
Weighted-average number of shares - diluted
Weighted-average number of shares-diluted (in shares)
Document and Entity Information [Abstract]
The amount of acquisition cost of a business combination allocated to property, plant and equipment to be used in ongoing operations.
Business Entity Acquisition Purchase Price Allocation Property Plant And Equipment
Remaining HPPD assets acquired
Amount of acquisition cost of a business combination allocated to other assets not separately disclosed in the balance sheet.
Business Entity Acquisition Purchase Price Allocation Other Assets
Other
The amount of acquisition cost of a business combination allocated to an identifiable intangible asset that will be amortized.
Business Entity Acquisition Purchase Price Allocation Amortizable Intangible Assets
Acquired intangible assets
Purchase Price Allocation [Abstract]
Purchase Price Allocation [Abstract]
Manufacturing agreement designated as an intangible asset.
Manufacturing Agreement [Member]
RSDL, a product of HPPD.
RSDL [Member]
Contingent consideration measured by net sales of a product.
Contingent Consideration Percentage Of Net Sales
Contingent consideration, percentage of RSDL net sales (in hundredths)
Maximum percentage applied to net sales for contingent consideration from August 1, 2013 through July 31, 2028.
Contingent Consideration Maximum [Member]
Contingentconsidertaionrange [Member]
Minimum percentage applied to net sales for contingent consideration between August 1, 2013 and July 31, 2028.
Contingent Consideration Minimum [Member]
Contingentconsiderationlowrange [Member]
The second period of contingent consideration.
Contingent Consideration Period Two [Member]
October 1, 2015 through September 30, 2016 [Member]
The first period of contingent consideration.
Contingent Consideration Period One [Member]
August 1, 2013 through September 30, 2015 [Member]
The total cost of the acquired entity including the cash paid to shareholders of acquired entities, fair value of debt and equity securities issued to shareholders of acquired entities, the fair value of the liabilities assumed, and direct costs of the acquisition.
Business Entity Acquisition Purchase Price
Total estimated purchase price
Fair value, as of the acquisition date, of potential payments under the contingent consideration arrangement including cash and shares.
Business Entity Acquisition Contingent Consideration At Fair Value
Fair value of contingent purchase consideration
Amount of cash paid to acquire the entity.
Business Entity Acquisition Cost Of Acquisition Cash Paid
Amount of cash paid to Bracco Diagnostics, Inc.
Purchase Price [Abstract]
Purchase Price [Abstract]
HPPD a division of Bracco.
HPPD [Member]
Tabular disclosure of all of the fair values of the purchase price and assets and liabilities acquired in a business combination.
Schedule of Business Purchase Price Allocation [Table Text Block]
Schedule of Purchase Price Allocation
Schedule of preliminary purchase price including but not limited to cash paid and fair value of contingent consideration.
Schedule of Preliminary Purchase Price [Table Text Block]
Schedule of Preliminary Purchase Price
Fair value measurement of contingent value rights granted to former shareholders and stock option holders of Bracco Diagnostics Inc. for net sales of RSDL
Change In Fair Value Of Contingent Purchase Consideration
Change in fair value of contingent purchase consideration
Number of business units under the entities reporting segments.
Number of business units
Segment of the Company which develops, manufactures and commercializes vaccines and antibody therapies for use against biological agents that are potential weapons of bioterrorism or biowarfare.
Biodefense [Member]
Revenue received for business interruption insurance recovery.
BusinessInterruptionInsuranceRevenue
Business Interruption Insurance Recovery
Business Interruption Insurance Recovery [Text Block]
Business Interruption Insurance Recovery [Abstract]
A plan adopted by the Company in November 2010 to restructure and reprioritize the operations of Emergent Product Development UK Limited ("EPDU").
EPDU Restructuring Plan [Member]
EPDU Restructuring Plan [Member]
Segment of the Company which develops vaccines, antibody therapies and technology platforms for use against infectious diseases, oncology, autoimmune and inflammatory disorders and other medical conditions that have resulted in significant unmet or underserved public health needs.
Biosciences [Member]
Maximum amount of consideration to be received from the achievement of sales milestones under the collaborative agreements.
Maximum payments to be received for achievement of sales milestones
Maximum payments to be received for achievement of sales milestones
Maximum amount of payments to be received from collaborators for the regulatory filings and approvals.
Maximum payments to be received for regulatory filings and approvals
Maximum payments to be received for regulatory filings and approvals
Maximum amount of consideration to be received from the achievement of clinical and development milestones under the collaborative agreements.
Maximum payments to be received for achievement of specified clinical and development milestones
Maximum payments to be received for achievement of specified clinical and development milestones
Represents an optional service period over which a party is obligated to provide service under a collaborative arrangement.
Collaborative arrangement, optional service period
Optional service period
Represents the number of optional service periods that may be exercised by the counterparty under a collaborative arrangement.
Collaborative arrangement, number of optional service periods
Number of optional service periods
Initial service period over which a party is obligated to provide service under a collaborative arrangement.
Collaborative arrangement, initial service period
Initial service period
Represents the period of a prior written notice required for a termination without cause by the counterparty to a collaborative arrangement.
Collaborative arrangement, period of prior written notice required for termination without cause
Period of prior written notice required for termination without cause
The period over which the collaborative arrangement remains in effect after first commercial sale of any product licensed.
Collaborative arrangement, term after first commercial sale of any product licensed
Term of collaborative arrangement after first commercial sale of any product licensed
A specific collaborative product arrangement with Pfizer Inc.
Pfizer CD20 [Member]
A specific collaborative product arrangement with Abbott Laboratories.
Abbott Laboratories TRU016 [Member]
Collaboration Agreements [Abstract]
OETC loan draw down
OETC Loan
Represents a Variable Interest Entity in which the company is primary beneficiary. A collaboration with Temasek Life Sciences Ventures Pte Limited to advance the development of monoclonal products for worldwide prophylaxis or treatment of infection caused by existing or anticipated future pandemic influenza strains via a hemagglutinin-based medical countermeasure, resulting in the formation of EPIC Bio Pte Limited ("EPIC").
EPIC Bio Pte Ltd [Member]
Represents a Variable Interest Entity in which the company is primary beneficiary. A collaborative arrangement with the University of Oxford ("Oxford") and certain University of Oxford researchers to conduct clinical trials in the advancement of a vaccine product candidate for tuberculosis, resulting in the formation of the Oxford-Emergent Tuberculosis Consortium ("OETC").
Oxford Emergent Tuberculosis Consortium [Member]
Fair value of share-based compensation awards vested. Includes options, share units, stock appreciation rights, and restricted stock.
Share based Compensation Arrangement by Share-based Payment Award, Awards Vested in Period, Fair Value
Total fair value of awards vested
The intrinsic value of non vested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.
Share Based Compensation Arrangement, Equity Instruments other than Options, Outstanding, Aggregate Intrinsic value
Outstanding, beginning of period
Outstanding, end of period
Represents immaterial errors in prior period financial statements that were corrected in the current fiscal period.
Cash flow presentation of the excess tax benefit attributable to exercise of stock options and restricted stock units [Member]
Represents the Company's 2012 Employee Stock Purchase Plan.
Employee Stock Purchase Plan [Member]
Treasury Stock [Abstract]
Stock Repurchase Plan of 2012.
Stock Repurchase Plan of 2012 [Member]
Amount of purchases, sales, and issues in relation to liabilities measured at fair value on a recurring basis using unobservable inputs (level 3).
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, Sales, Issues
Purchases, sales and issuances
The fair value amount of a type of right given to shareholders of an acquired company (or a company facing major restructuring) that ensures they receive additional benefit if a specified event occurs.
Fair value of contingent value rights issued
Fair value of CVRs issued
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents a type of right given to shareholders of an acquired company (or a company facing major restructuring) that ensures they receive additional benefit if a specified event occurs.
Contingent Value Rights, Fair Value Disclosure
Contingent purchase consideration
Represents the period over which options can be exercised from the date of grant.
Share Based Compensation Arrangement by share Based Payment Award, Options, Exercise Period
Exercise period of options, maximum
The contractual life of awards made under a stock-based employee compensation plan.
Share Based Compensation Arrangement by share Based Payment Award, Contractual life of awards
Contractual life of awards
Minimum exercise price of option as percentage of the fair market value of the shares underlying such option on the date of grant.
Exercise price of option as percentage of fair market value at grant date, minimum
Exercise price of option as percentage of fair market value at grant date, minimum (in hundredths)
Represents the number of shares of common stock available for issuance under the 2006 Plan for each restricted stock unit granted.
Restricted stock unit conversion ratio
Restricted stock unit conversion ratio
Represents the number of stock-based compensation plans the company maintains.
Number of stock based employee compensation plans
Refers to the Company's two stock-based employee compensation plans, the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "2006 Plan") and the Emergent BioSolutions Employee Stock Option Plan (the "2004 Plan").
Emergent Plans [Member]
A share-based compensation plan adopted by the Company in 2004.
Emergent BioSolutions Employee Stock Option Plan [Member]
2004 Plan [Member]
A share-based compensation plan adopted by the Company in 2006.
Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]
2006 Plan [Member]
Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.
Property, Plant and Equipment Useful Lives Table Text Block [Text Block]
Estimated useful lives of property, plant and equipment
Disclosure of accounting policy for the risk factors inherent in the entity's business, excluding risks associated with certain significant estimates or concentration risks.
Risks and uncertainties [Policy Text Block]
Certain risks and uncertainties
The cash outflow for contingent value rights.
Contingent value right payment
Contingent value right payment
The cash inflow from a contractual arrangement with the lender, including line of credit and long-term indebtednesses, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.
Proceeds From Borrowings On Long Term Indebtness And Line Of Credit
Proceeds from borrowings on long-term indebtedness
Fair value measurement of contingent value rights granted to former shareholders and stock option holders of Trubion Pharmaceuticals for certain developmental, regulatory or commercial milestones.
Provision For Fair Value Of Contingent Value Rights
Change in fair value of contingent value rights
Carrying value as of the balance sheet date of the noncurrent portion of liabilities incurred and payable to Bracco Diagnostics for net sales of RSDL.
Contingent Value Rights Net Of Current Portion
Contingent purchase consideration, net of current portion
Carrying value as of the balance sheet date of the current portion of liabilities incurred and payable to Bracco Diagnostics for net sales of RSDL.
Contingent Value Rights Current Portion
Contingent purchase consideration, current portion
Carrying amount of purchased research and development assets acquired in a business combination that have an indefinite life until completion or abandonment of the associated research and development efforts.
In process research and development
In-process research and development assets